Neuroendocrine carcinoma of the gallbladder
Prepared with OnCo (onco.cc/prep/gallbladder-neuroendocrine-carcinoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
9 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Synaptophysin, chromogranin A and CD56 on immunohistochemistry, Ki-67 proliferation index, Loss of pRB or p16 and mutant-pattern p53, Serum chromogranin A, Share of neuroendocrine versus adenocarcinoma component), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (localised disease), which of the standard options do you recommend and why?
- 6.For my situation (advanced disease), which of the standard options do you recommend and why?
- 7.Am I a candidate for Cisplatin, and what side effects should I expect?
- 8.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 9.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
The words I may hear
- Lymphovascular invasion (LVI): The pathologist has seen cancer cells inside small lymph or blood vessels in the removed tissue: a sign the tumour has found the exit routes, even if the nodes are clear.
- Perineural invasion (PNI): Cancer cells growing along the sheath of a nerve.
- Radical (extended) cholecystectomy: The cancer operation for gallbladder cancer: the gallbladder (if still present) is removed together with a rim of the liver it sits against and the lymph nodes along the bile duct and liver blood vessels.
- Grade: How abnormal the cancer cells look under the microscope, from grade 1 (close to normal, slow) to grade 3 or 4 (wildly abnormal, fast).
Tests and results to bring
Biomarker results to ask for: Synaptophysin, chromogranin A and CD56 on immunohistochemistry, Ki-67 proliferation index (median 70 percent), Loss of pRB or p16 and mutant-pattern p53, Serum chromogranin A (proposed), Share of neuroendocrine versus adenocarcinoma component.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Localised disease: Resection as for gallbladder cancer where feasible; surgery and adjuvant chemotherapy were each associated with better survival in population data. (Radical (extended) cholecystectomy, Extrapulmonary neuroendocrine carcinoma)
- Advanced disease: Platinum and etoposide chemotherapy as for other extrapulmonary neuroendocrine carcinomas, rather than the gemcitabine and cisplatin used for adenocarcinoma. (Extrapulmonary neuroendocrine carcinoma, Cisplatin, Grade 3 well-differentiated neuroendocrine tumour)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.